This story originally ran on March 9 and has been updated to provide more details and comment.

A new clinical trial is using proteomics technologies to help guide doctors to make personalized treatment regimens for patients with breast cancer.

The trial, which is funded by the Side-Out Foundation, is being managed by TGen Drug Development, a partnership between the Translational Genomics Research Institute and Scottsdale Healthcare to bring genomics and proteomics discoveries made by TGen and others to the bedside.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.